Elevation Oncology, Inc. (ELEV)
| Previous close | 3.7000 |
| Open | 3.7600 |
| Bid | 3.6700 x 100 |
| Ask | 3.7900 x 100 |
| Day's range | 3.6700 - 3.8881 |
| 52-week range | 0.3630 - 5.8900 |
| Volume | |
| Avg. volume | 1,038,443 |
| Market cap | 203.254M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.75 |
PR NewswireElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.
- PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
- GuruFocus.com
Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023
Strategic Advances Amidst Financial Prudence
